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Abstract 
Every year around 8.2 million people die due to cancer, in Portugal, breast 
cancer is the leading cause of women death (in cancer patients). Several risk factors 
could be pointed being age (over 50 years old), gender (females), reproductive and 
hormonal factors and genetic predisposition (presence of mutations in BRCA 1 and 
BRCA 2) the most commons. Staging is done regarding several aspects, e.g.: histology, 
histopathologic localization, hormone receptors, mutations or expression of cluster 
genes. 
Research from last decades is focused into targeted therapies. MGP, matrix Gla 
protein, was pointed as a possible target. MGP primary structure consists in a signal 
peptide, a phosphorylation domain and a γ-carboxylase recognition site. MGP has also 
five Gla residues. For a long time, only an isoform with four exons was known, but 
recently was discovered a second isoform with five exons, with three additional putative 
binding sites, conferring, possible, a higher binding capability as well as a presumably 
higher calcification inhibitory power. 
Although MGP role in cancer is not fully understood, being upregulated in some 
types of tumors and downregulated others, in breast cancer, was established, as a 
prognostic factor, being overexpressed in poor diagnose cases.  
Being MGP role in tumorigenesis to be defined, the aims of this work were: 
clarify MGP expression in normal vs tumoral tissue (using in silica method – TCGA 
database); as well as clarify regulatory mechanisms of MGP (TCGA database); analyze 
expression of each isoform in breast cancer cell lines (results were obtained performing 
qRT-PCR followed by electrophoresis and sequencing of the extracted bands) and 
assess the result of overexpression of each isoform (using XTT and wound healing 
assay).  
We could conclude that both variants could be expressed in simultaneous. Every 
cell line presented E4 isoform but just a few presented E5 isoform. Hound healing assay 
revealed that an overexpression of E4 and E5 variants slow down the rate of the area 
invaded by migrating cells, specially an overexpression of E4 isoform. After in silica 
analyze we could conclude that MGP is more expressed in tumoral tissue vs normal 
tissue, existing a negative correlation between MGP expression and mir155 expression 
and methylation, that means that: in tumoral tissue mir155 is less expressed than in 
normal tissue and occurs an hypomethylation in tumoral tissue. Knowing that MGP 
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inhibits calcification and is correlated with angiogenesis, our hypothesis is that 
overexpression of MGP in tumoral tissue is a mechanism of cancer to facilitate 
angiogenesis – a hallmark of cancer.  
 
Keywords: Breast Cancer; MGP, mir155; prognostic factor, angiogenesis, 
calcification inhibition.  
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Resumo 
 
 Introdução: o cancro é caracterizado por um crescimento anormal e 
incontrolado de células que podem adquirir características malignas por acumulação de 
mutações. Hanahan and Weinberg (2000) descreveram que o desenvolvimento tumoral 
baseado em vários passos está assente na aquisição, por parte do tumor, de seis 
princípios biológicos: i) manter sinalização proliferativa; ii) desenvolver mecanismos de 
defesa contra supressores de crescimento; iii) resistir á morte celular; iv) ativar 
imortalidade replicativa, v) induzir angiogénese e vi) ativar invasão e metástase. Se uma 
visão mais tradicional atribuía estas alterações ao resultado de mutações genéticas, uma 
visão mais atual do cancro engloba também a epigenética como fator crucial na 
repressão e ativação de genes capazes de conferir as características malignas aos 
tumores; a metilação genómica é um exemplo de um mecanismo já descrito com um 
papel importante na atividade tumoral, sendo que está associado a hipometilação do 
genoma com o cancro.  
Determinar os mecanismos moleculares desta doença aproximam a população 
científica de terapias alvo que permitam ajudar a controlar a disseminação desta doença 
que é considerada pela organização mundial de saúde uma doença epidémica em 
ascensão. Todos os anos morrem no mundo 8.2 milhões de pessoas devido a cancro 
(cerca de 13% de todas as mortes do mundo), sendo a segunda causa de morte em 
Portugal, EUA e Europa. Em Portugal, o cancro do pulmão e brônquios é a primeira 
causa de morte por cancro nos homens, enquanto que a primeira causa de morte por 
cancro nas mulheres é o Cancro da Mama (CM). Existem vários fatores de risco para o 
CM, sendo os principais: i) idade acima dos 50 anos; ii) ser do sexo feminino (apenas 
1% dos casos corresponde a homens); iii) história pessoas ou familiar de CM; iv) 
fatores reprodutivos e hormonais; v) exposição endógena a estrogénios (como p.e. uso 
da pílula) e vi) predisposição genética (comumente mutação nos genes BRCA1 e 
BRCA2). O estadiamento da doença é feito usando TNM (avalia tamanho do Tumor, 
Nódulos e Metástases). Contudo, outras características são usadas em cancro para 
definir o tratamento, nomeadamente: localização histopatológica (divide os carcinomas 
in situ dos carcinomas invasivos); expressão de determinados recetores hormonais e 
expressão de genes em clusters/aglomerados (conferindo a divisão em Luminal A, 
Luminal B, HER2 e tipo basal), sendo que nas últimas décadas tem se procurado 
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encontrar terapias direcionas, sendo que cada vez mais se procuram novos alvos 
terapêuticos.  
Um possível alvo terapêutico é a MGP (proteína Gla da matriz). Está localizada 
no braço pequeno do cromossoma 12 (12p12.3) e é uma proteína dependente da 
vitamina K. A sua estrutura primária consiste num péptido de sinal, um domínio de 
fosforilação e um local de reconhecimento da γ-carboxilase; tem também cinco resíduos 
Gla que após conversão pela enzima γ-glutamil carboxilase passam a ter uma maior 
afinidade para minerais e iões minerais (como o cálcio, fosfato e cristais de 
hidroxiapatite – componentes minerais do esqueleto). Durante muito tempo apenas uma 
variante era conhecida E4 (quatro exões) contudo foi identificada uma nova isoforma: 
E5 (cinco exões), que apresenta três locais putativos adicionais de ligação a γ-
carboxilação; esta característica pode provocar um aumento da sua capacidade de 
ligação, levando a um poder inibitório mais forte. MGP está associada à inibição de 
calcificação (devido à sua afinidade de ligação mineral e iónica), e mutações neste gene 
estão associadas a aterosclerose (calcificação vascular), síndrome de Keutel e cancro. 
No caso do cancro estudos revelam um papel na diferenciação, proliferação e migração 
celular, no início da angiogénese e na tumorigénese. Contudo o seu papel na 
oncogénese e a correlação entre a sua expressão e o tipo de tumores está ainda por 
determinar; sendo que para alguns tipos de tumores, apresenta maior expressão no 
tecido tumoral e em outros mais em tecido normal. No cancro da mama contudo, tem 
sido apontado como fator de prognóstico, estando a sua sobreexpressão associada a um 
pior prognóstico.  
Objectivos: Estando o papel da MGP no cancro ainda por definir, o principal 
objetivo deste trabalho passa por tentar correlacionar a sua expressão em tecido normal 
e tumoral assim como em subgrupos de pacientes; clarificar a expressão das variantes 
em linhas celulares do cancro da mama, assim como qual o resultado a sobreexpressão 
das variantes na proliferação e migração celular e, identificar mecanismos regulatórios 
da MGP e o sua expressão em tecido normal vs tumoral.  
Materiais e métodos: Para cada linha celular foi averiguado qual a(s) 
variante(s) expressa(s), recorrendo para isso a qRT-PCR e posteriormente a uma 
confirmação por sequenciação das bandas obtidas por electroforese, das amostras do 
qRT-PCR. O efeito da sobreexpressão das isoformas na proliferação e migração celular 
foi avaliado em duas linhas celulares da mama (linhas não comerciais) previamente 
transfetadas com o plasmídeo de interesse (E4, E5 e um vector vazio usado como 
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controlo) que foram sujeitadas a ensaios de XTT e do risco. A relação entre a expressão 
da MGP em tecidos tumorais, assim como a análise da expressão do mir155 foi 
averiguada recorrendo a um estudo in silico a partir da base de dados The Cancer 
Genome Atlas (TCGA). Usou-se esta ferramenta também para avaliação da metilação de 
quatro CpGs da MGP. Contudo, fez-se também uma avaliação de uma CpGs na linha 
celular de cancro da mama T47D, fazendo inicialmente um tratamento com 5-
azacitidina para desmetilar o genoma. A análise da metilação foi feita recorrendo a um 
tratamento com bissulfito e posterior análise por PCR.  
Conclusão: As duas variantes podem ser expressas em simultâneo, sendo que 
em todas as linhas celulares em estudo foi comprovada a expressão da variante E4, já a 
variante E5 não foi detetada em várias linhas celulares. Ensaio do risco mostrou que 
uma maior expressão da MGP (tanto variante E4 como E5, sendo que na variante E4 os 
resultados foram mais significativos) parece promover uma diminuição da taxa de 
migração celular, sendo que após as 72h de ensaio as células não transfectadas (ou 
transfetadas com vetor vazio) tinham já ocupado 100% da área, enquanto que as células 
transfetadas com E5 só foi possível verificar os 100% às 96h, e nas células transfetadas 
com E4 ao fim das 96h ainda não tinha ocorrido 100% de área invadida.  
Os ensaios in silico demostraram que a MGP está mais expressa no tecido 
tumoral, e que há uma correlação negativa entre expressão da MGP e metilação 
(ocorrendo uma hipometilação no tecido tumoral) assim como com a expressão de 
mir155. Sabendo que MGP inibe calcificação e, está relacionada com a angiogénese, 
parece que a maior expressão da MGP em tecido tumoral seja um mecanismo do tumor 
para promover a angiogénese – uma marca do cancro (Hallmark of Cancer).  
Palavras-chave: Cancro da mama; MPG; mir155; factor de prognóstico, 
angiogénse, inibição da calcificação  
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Chapter I – Introduction 
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The genetic material of life 
The mathematician and philosopher Norbert Wiener based on Schrodinger’s 
descriptions said that “just as the amount of information in a system is a measure of its 
degree of organization, so the entropy of a system is a measure of its degree of 
disorganization” 1, this theoretical concept applies to everything known in this universe 
even when we are not able to understand the connection between the information.
2
 This 
mathematician put the focus on information, and its importance. The seek for 
information is as old as life, and due to last decades technology improvement, the 
pursuit for information had a big revolution and was rich in a wide-ranging fields, this 
revolution allowed, for instance, the birth of genetic as a science, contributing to answer 
big questions like:
3
  
 How information is regulated and transmitted cell to cell in a 
multicellular organism, holding the information almost unaffected; 
 What molecule is able to replicate almost limitless in such precise way; 
  How the information is organized in order to allow storing so much 
information in a space as small as a cell.  
Slowly these questions were answered and some 1940s studies were very 
important, because they showed that: 
3
 
 Proteins work as “building blocks” in cells and they have a play in 
almost all cell’s functions; 
 Deoxyribonucleic acid (DNA) was likely the carrier of genetic 
information. 
3
;  
One of the biggest finding of 20
th
 century was “the structure of DNA and the 
mechanisms by which information coded in DNA is translated into the amino acid (aa) 
sequence of proteins”,4 without these findings scientific perspective of inheritance 
probably would still be almost none and based on empirical data, turning biological 
disciplines like modern cancer research a “descriptive science that cataloged diverse 
biological phenomena without being able to explain the mechanics of how they occur.” 
5
 
 
Constitution and Structure of DNA 
Deoxyribonucleic acid is the combination of two poly-nucleotide chains 
(strands), arranged in a double helical structure, with a sugar-phosphate backbone 
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attached to a set of pyrimidine (thymine (T) and cytosine(C)) and purine (adenine (A) 
and guanine (G)) bases. Sugar molecules – deoxyribose – are connected by a 
phosphodiester bond from the 5’ position of one deoxyribose to the 3’ position of the 
next. The helical structure is held by hydrogen bonds between bases, which have a 
specific way to bound between them, thymines only bond to adenines and cytosines 
only bond to guanines. To a set of one base (A, T, C or G) and a sugar is given the name 
of nucleoside if the molecule has phosphate group(s) is called nucleotide. 
3,4
 
In most multicellular organisms genetic information carried in each cell is the 
same;
6
 to make that happen cells undergo semiconservative replication of DNA – using 
both strands of a DNA molecule to produce two complete double helices, is called 
semiconservative because each original (parental) strand serve as template for new 
(daughter) strand (Figure 1). Replication have error associated (one error per 10
7 
nucleotides copied) as well as correction machinery that correct 99%, still some errors 
are not corrected - mutations. 
3
 
 
Cancer Genetics 
Cancer is usually characterized by an abnormal growth and uncontrolled 
proliferation of cells. Cells undergo several dynamic processes in which they can 
acquire genetic changes, that provoke, for instance, loss of response for several signals 
controlling cellular growth and death, therefore, an accumulation of genetic alteration 
Figure 1 | Scheme of semiconservative replication, each strand is used as a template for the new double helix. 
Replication is semiconservative because each daughter DNA double helix is composed by a conserved strand and 
newly synthesized strand.  Originals strands remain intact for many cell generations. Adapted from Alberts  et al 
(2010)3 
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can occur in somatic cells, resulting sporadic cancers, or in germline cells causing 
hereditary predisposition to cancer.
7–10
 Although mutations occur aleatory, cancer is a 
result of mutations in three types of genes: oncogenes (cells promoting cell growth and 
survival – with gain-of-function mutations), tumor suppressor genes (inhibitors of cell 
growth and survival – with recessive loss-of-function)5,11 and stability genes (caretakers 
– that maintain DNA mechanisms and repair errors). 11,12 
Hanahan and Weinberg (2000) described that tumors acquire six biological 
principles during multistep development (Figure 2):
10
 sustaining proliferative signaling; 
evading growth suppressors; resisting cell death; enabling replicative immortality; 
inducing angiogenesis and activating invasion and metastasis.
10,13
 
After a decade of conceptual progress The Hallmarks of Cancer “continue to 
provide a solid foundation for understanding the biology of cancer”; even though they 
reevaluated new findings and added two emerging and two enabling characteristics to 
hallmarks (traits) list, revealing that tumorigenesis cannot be just defined by self traits 
but also regarding tumor microenvironment (Figure 3).
10
 
Figure 2 | Hallmarks of cancer. Adapted from Hanahan. and Weinberg (2000) 
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Traditional view of cancer describes it as an accumulation of genetic 
alteration/mutation, but several studies regarding epigenetic
14
 (study of heritable 
changes in gene function that not entail a change in DNA sequence
15,16
) showed that 
alterations in the epigenome have an important role in gene activation and repression 
regulation related to cancer. These heritable changes are disseminated as “covalent 
chemical changes to the cytosine bases and are referred to as DNA methylation”.16 
Epigenetic regulation and chromatin compaction also understand histone tail 
modifications, ATP-dependent chromatin remodeling or non-coding RNA (ribonucleic 
acid) play, yet heritability is less clear. 
16
 
 
DNA Methylation  
Involved in several epigenetic processes like “gene expression, imprinting, X 
chromosome inactivation, silencing of retroviral and transposable DNA elements, and 
chromatin organization,”16 assuring proper regulation of gene expression and stable 
gene silencing.
17
 In cancer DNA is usually hipomethylated.
18
 
Methylation is a covalent addition of a methyl group (-CH3) that occurs “exclusively at 
the 5 position of the cytosine moiety” catalyzed by DNMT (DNA methyltransferase), 
this occurs within CpG islands
a
 dinucleotides (Figure 4).
17
 An alteration in gene 
expression caused by methylation could lead to an oncogene activation or inactivation 
of a tumor suppressor gene, increasing cancer risk.  
                                                 
a
 CpG islands are short interspersed DNA sequences rich in guanidine and cytosine (GC).
103
 
Figure 3 | Emerging Hallmarks and Enabling Characteristics. Adapted from Hanahan and Weinberg (2011) 
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Epidemiology 
Cancer is considered a rising epidemic disease
19
. Each year, worldwide appears 
approximately 14 million new cases of cancer and 8.2 million people die from cancer; 
this represents 13% of all death worldwide.
19,20
 In United States as in Portugal cancer is 
the second leading cause of death, but is expected to overcame heart diseases in the next 
few years.
20–22
 In 2016 around 595 690 Americans are expected to die due cancer, this 
represents an average of 1 630 death per day.
21
  
Using trends, in cancer death rates to measure the improvement of the battle 
against cancer, is possible to see that in the 20
th
 century, the total cancer death rate was 
high, reaching a peak in 1991 (Figure 5), this peak is often explained by the tobacco 
epidemic.
21
 Tobacco intake is associated as a risk factor for numerous tumors like 
“lung, larynx, oesophagus, oral cavity and pharynx, bladder, pancreas, kidney, liver, 
stomach, bowel, cervix, leukemia, and ovarian cancers”.21 So was expected that a 
decrease of its consumption – happened in the 70’s in United Kingdom (UK)23 and 
United States of America (USA)
24
, e.g. – would lead to a decrease of cancer death, but 
Figure 4 | Cytosine methylation. A) Methylation occurs at position 5 of cytosine moiety (marked with an [*], the 
process is catalyzed by DNMT. B) Within the promoter regulation region, unmethylated CpGs (dark brown) allow 
gene expression; when methylation occurs gene becomes silenced. Adapted from Kulis, M. and Esteller, M. (2010). 
17  
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Figure 5 | Trends in cancer incidence and death rates by sex, 
in USA between 1975 and 2011 – adapted from Siegel et al 
(2015)20 
Figure 6 | Ten leading cancer types by sex in American citizens. A) Estimated new cases; B) Estimated 
deaths. Estimates are rounded to the nearest 10 and excludes cases of basal cell and squamous cell skin cancers and in 
situ carcinoma except urinary bladder – adapted from Cancer Statistics, Siegel (2015) 
that just happened between 1991 and 
2012 (rate lowed in 23%).
20
 This is 
explained by the fact that usually is 
necessary many years, or decades, for 
the damages in DNA caused by 
smoking lead to cancer. The 
improvement in early detection and 
treatment is pointed as well as a cause 
of the reduction of cancer death.
20
 
 
In USA, in spite of in both 
males and females the leading cause of 
death by cancer is lung and bronchus 
cancer, incidence is gender specific – prostate cancer in men and breast cancer (BC) in 
women (Figure 6).
20
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In Portugal mortality rates are quite different (Figure 7), in males lung and 
bronchus tumors are still the leading cause of death, but in females the first position is 
taken by breast cancer (lung and bronchus are in fifth place). Colorectal cancer is the 
second major cause of cancer in Portugal, in both genders. Although, cancer incidence 
in Portugal as is USA is gender specific. 
25
 
 
Breast Cancer 
Epidemiology 
Breast cancer is a disease that affects many people worldwide, in specially 
women. In United States, 29% of the new cases of cancer in women are breast cancer, it 
is the second leading cause of death in women with cancer, representing 15% of the 
deaths
20
, in Portugal that number rises to 17%.
25
  Cancer statistics 2015 show that new 
cases and deaths in men represents only 1% of all cases,
20
 the same was assessed to 
Portuguese population.
26
 Comparatively to worldwide the incidence of BC in Western 
Europe is higher, although, Portugal have the smallest rate of mortality (in comparison 
with other European state members). In part this could be a result of early detection, 
promoted by mammographies screenings, that in 2016 is expected to reach 60% of 
coverage of women (between 45 and 69 years old).
27
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Figure 7 |A) Mortality by gender in Portugal (2000-2012); B) Incidence by gender in Portugal. Adapted 
from World Health Organization (2014) 
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Risk factors 
There are some risk factors associated with breast cancer and they are commonly 
seen in about 50% of woman diagnosed. Those risk factors could be: 
– Age – above 50 years old28,29; 
– Gender – occurs about 150 times more in females than in males; 
– Lifestyle, diet and environment factors; 
– Personal or family history of breast cancer or benign disease; 
– Hormonal and reproductive factors – females with no pregnancies – nulliparity 
– or pregnancies in an age greater than 30 years old, early menarche and late 
menopause; 
– Endogenous estrogen exposure/reproductive factors;  
– Genetic predisposition.28 
 
Hormonal risk 
As we saw above, hormones play a tremendous role in breast cancer, and it have 
been demonstrated that an increased estrogen exposure is correlated with an increasing 
risk of cancer, these suggests a hormone dependence.
28,30
 Although the cancer risk, 
estrogen is essential for breast development and for the reproductive system. The 
number of menstrual cycles a woman goes throw in her life will be determinant to 
define her cancer risk because natural estrogen (produced in self organism) is “released 
from ovaries during every menstrual cycle”30. This way: women with earlier menarche 
and late menopause are exposed to more natural estrogen
28,30
; for each year earlier from 
the average menarche (12 years old) the risk increases by 5% ,
30,31
 and for late 
menopauses the risk increases 3% per year.
30
 In other hand having children is benefic to 
women due to a lack of periods during the pregnancy, this could be a risk factor for 
western societies where women delayed giving birth and have less children; each 
pregnancy is thought to lower the risk in 7%. 
30
 The risk could be lowered even further 
by breastfeeding [4.3% for every 12 months], studies suggest that breast cells could be 
changed in the process, making them less prone to develop cancer. 
30,32,33
 
Women use hormones commonly as a contraceptive (the pill) or as a post-
menopausal Hormone Replacement Therapy (HRT), this increases slightly breast cancer 
risk
30,34–36
. Notwithstanding, the risk vanishes slowly after quitting, being null after 10 
years quitting the pill 
30,37
 and after 5 years after stopping HRT.
28,30
 The risk, is higher 
using combined therapy of estrogen and progestin compared with using estrogen 
10 
 
alone.
28
 In spite of the risk, big number of menopausal patients use HRT to relieve 
biological changes like hot flashes, vaginal dryness or as a way of protection against 
osteoporosis or other diseases of bone.
28,38
  
 
 
 
Genetic risk  
Between 70-80% (Figure 8) of breast cancer cases are due to sporadic cases (mix 
of genetic damages obtained over a lifetime) and a small percentage due to hereditary 
causes (genetic alterations passed by one generation to another) and family clusters 
(bigger percentage of breast cancer in a same family considering rate of sporadic 
cancer; putting in evidence a combination of risk factors like inherited susceptibility and 
environmental factors).
39
 
Breast cancer 1 and 2 genes (BRCA1 and BRCA2) are the cause of most 
hereditary breast cancer cases, but mutations can occur also in PTEN, p53, MLH1, 
MLH2 and STK11.
28
 BRCAs are autosomal dominant genes that encode tumor 
suppressor protein, which help repair damaged DNA, playing an essential role in cell 
stability. When either of one is mutated or altered causing a malfunction of the protein, 
DNA may not be repaired properly and additional genetic alteration could lead to 
cancer. Specific mutations in these genes not only increase female risk of breast cancer 
but also ovarian cancers. Is known that 12% of woman in general population will 
develop breast cancer during their lives; recent studies show that 55 to 65% women 
with harmful mutations in BRCA1 and 45% with harmful mutations in BRCA2 will 
Figure 8 | Distribution of breast cancers cases by sporadic vs hereditary cancer. Adapted 
from Staten Island University Hospital (2014)39 
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develop breast cancer by the age of 70 years old. 
40
 
 
Staging 
For staging it is mandatory doing a microscopic confirmation where the 
histologic type and grade should be recorded. Staging for carcinoma of the breast 
applies to infiltrating (including microinvasive) and in situ carcinomas. It is usually 
used TNM (Tumor, Node and Metastasis) classification of malignant tumors, published 
by the American Joint Committee on Cancer (AJCC) as staging system.
28,41
  
Physicians use results from scans and diagnostic tests to answer questions like: 
 
Anatomy 
Female breast is mostly composed by adipose tissue. Each breast is divided in 
lobes, lobules and milk ducts. A healthy breast have between 12 to 20 lobes (which one 
is formed by many smaller lobules
28
 – gland that produces milk in nursing woman). 
Lobules and lobes are connected by milk ducts that when necessary carry milk to the 
nipple. In adipose tissue a network of ligaments, fibrous connective tissue, nerves, 
lymph vessels, lymph nodes and blood vessels (Figure 9).
42
 
 
Lymph system 
The lymph is part of the immune system and work in a similar way of the 
circulatory system, where lymph vessels and nodes are running throughout the entire 
body to transport disease-fighting cells and fluids. Bean-shaped lymph nodes clusters 
“are fixed in areas throughout the lymph system act as filters by carrying abnormal cells 
away from healthy tissue”.  
“T (Tumor) – How large is the primary tumor? Where is it located? 
  N (Node) – Has the tumor spread to the lymph nodes? If so, where and how 
many? 
  M (Metastasis) – Has the cancer metastasized to other parts of the body? If so 
where and how much?”43 
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Usually the type of breast cancer is determined by the origin of the growth of 
cancer cells (usually in the lobes, lobules and ducts). Cancer found in nearby lymph 
nodes (LN) can help physicians determine if the tumor has spread; some additional 
distal nodes can be tested to understand how far the cancer has spread. 
 
Regional lymph nodes 
Axillary, transpectoral and internal mammary nodes are drained by the breast 
lymphatic vessels. For staging purposes intrammamary lymph nodes are coded as 
axillary, and supraclavicular lymph nodes are coded as regional lymph nodes. 
Metastasis to other lymph nodes (as cervical or contralateral internal mammary lymph 
nodes) are classified as distant (M1) (Figure 10)
28
  
Figure 9 | Female and breast anatomy. A) Female anatomy; B) Localization of lobules, lobes and milk ducts in 
breasts; C) Scheme of intrinsic systems in breast tissue and neighborhood. Adapted from National Breast 
Cancer Foundation (2015). 
Milk duct 
Lobe 
B 
C 
A Lobule 
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Figure 10 | Diagram of breast and regional lymph nodes. 
1 – Low axillary, Level I; 2 – Mid-axillary, Level II; 3 – High-
axillary, apical, Level III; 4 – Supraclavicular; 5 – Internal 
mammary nodes. 
1. Axillary (ipsilateral): interpectoral (Rotter’s) nodes and lymph nodes along 
axillary vein and its tributaries that may (but not required) divided into: 
a. Level I – low axilla  
b. Level II – mid-axilla 
c. Level III – apical axilla (more anatomical information in Appendix 
table 3) 
2. Internal mammary (ipsilateral): LN in the intercostal spaces along the 
edge of the sternum in the endothoracic fascia.  
3. Supraclavicular: LN in the supraclavicular fossa, a triangle defined by the 
omohyod muscle and tendon, the internal jugular vein, and the clavicle and 
subclavicle vein. Adjacent LN outside of this triangle are considered to be 
lower cervical nodes (M1). 
 
Classification 
1. Clinical staging 
The first step is a physical examination of the area, including observation and 
palpation of the skin, mammary gland and lymph nodes (axillary, supraclavicular and 
cervical), imaging and an examination of breast tissues and/or other tissues. 
28,41
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2. Pathologic staging  
Includes all previous information and data from “surgical exploration and 
resection as well as pathologic examination of the primary carcinoma, regional lymph 
nodes and, metastatic sites (if applicable) including not less than excision of the primary 
carcinoma with no macroscopic tumor in any margin of resection by pathologic 
examination.”41 
The pathologic stage (pT) only can be assessed if the marge involvement is 
microscopic and not macroscopic. If there is a macroscopic involvement the cancer is 
coded as pTX since the total extent of the primary tumor could not be measured. If the 
primary tumor is invasive and not just microinvasive it is recommended at least the 
resection of the low axillary lymph nodes (Level 1) (Figure 10) this is used for 
pathologic classification (pN). If the surgery occurs after “neoadjuvant therapy, 
hormonal therapy, immunotherapy, or radiation therapy, the prefix “y” should be used 
with the TNM classification” (e.g. ypTNM)41 
 
TNM Classification 
A. Primary Tumor (T) 
For each case, it is used a specific kind of measurement to classify the primary 
tumor; it could be obtained by physical examination or mammographies and 
ultrasounds. Only the invasive component is measured, after that it is removed tissue to 
prosecute some specific studies, for instance, to evaluate estrogen and progesterone 
receptors. Some patients have to do multiple core biopsies, this could lead to an under 
classifying of the T component, in that cases tumor size should be reconstructed based 
on imaging and histological findings. 
41
  
Applying TNM for staging the letter “T” is grouped to a number or letter to 
define the size and location. Some stages have some smaller groups – sub stages – to 
describe the tumor in more detail
43
 
TX: As said previously, is used when the primary tumor cannot be 
evaluated.
28,41,43
  
TO: There is no evidence of breast cancer. 
28,41,43
 
Tis – Carcinoma in situ, with no evidence of an invasive component41, its 
restricted within ducts or lobules of the breast tissue. 
41,43
 Tis is sub divided in three 
types: 
15 
 
Tis (DCIS) – Intraductal carcinoma in situ, is a noninvasive cancer, that can 
evolve to an invasive breast cancer if not removed. 
28,41,43
 
Tis (LCIS) – Lobular carcinoma in situ, called to abnormal cells found in the 
lobules or glands of the breast – in spite of not being cancer increases the risk of 
progress to invasive breast cancer. 
28,41,43
 
Tis (Paget’s) – Paget’s disease of the nipple28,41,43, “rare form of early, 
noninvasive cancer”43 that only affect skin cells of the nipple. Simultaneously can occur 
an invasive breast cancer, staging in this case is only given by the invasive tumor.
28,43
 
T1 – Tumor is no bigger than 20 millimeters (mm) in its widest area. It is 
subdivided usually in substages: 
T1mic – Microinvasion no larger than 1mm in the widest area.28,41 
T1a – Tumor is larger than 1mm but smaller than 5mm in the widest 
area.
28,41,43
 
T1b – Tumor larger than 5mm but not more than 10mm in the widest 
area.
28,41,43
 
T1c – Tumor larger than 10mm but not more than 20mm in the widest area. 
28,41,43
 
T2 – Tumor between 20mm and 50mm in the widest area. 28,41,43 
T3 – Tumor greater than 50mm. 28,41,43 
T4 – Tumor of any size with direct extension to: 28,41,43 
T4a – Chest wall, not including pectoralis muscle. 28,41,43 
T4b – Skin (Edema “[including peau d’orange] or ulceration of the skin of the 
breast, or satellite skin nodules confined to the same breast)”. 41 
T4c – Chest wall and skin. 28,41,43 
T4d – Inflammatory carcinoma. 28,41,43 
 
Notes: 
i. In case of bilateral breast carcinoma, each breast is considered an 
independent organ, this way both will have an independent stage. 
ii. Inflammatory carcinoma is characterized by “diffuse erythema and 
edema (peau d’orange) of the breast, often without an underlying 
palpable mass.”41 The symptoms are common to mastitis 
(inflammation of the breast). In this type of cancer, cancer cells block 
lymph vessels, causing the visual symptoms.
44
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iii. Carcinoma in situ – cancer located in epithelial cells is designated 
carcinoma. It occurs in glands and ducts, that is why most breast 
cancers are carcinomas. Benign (non-cancerous) cells do not invade 
beyond epithelial tissue, in carcinoma in situ abnormal cells look 
similar to invasive carcinoma cells (when analyzed under 
microscope). It was assumed that these cells could become invasive if 
not treated, but recent studies showed that the transition to invasive 
carcinoma is more “complex and subtle” than the previous idea based 
on microscopic resemblance. Long term follow-up of patients with 
carcinomas in situ established that not all of them progress to 
invasive cancer. 
45
 
 
B. Regional Lymph Nodes (N) 
Definitions for classifying the regional lymph nodes (N) are different for 
Clinical and for Pathologic classification. 
28,41,43,46
 
 
B.1. Clinical Classification28,41 
NX – Regional lymph node cannot be assessed (it could be removed previously, 
or not removed, e.g.). 
NO - No regional lymph node metastasis. 
N1 – Metastasis to movable ipsilateral axillary lymph nodes 
N2 - Metastasis in ipsilateral axillary lymph nodes fixed or matted (axillary 
lymph nodes that are fixed to each other), or in clinically apparent ipsilateral internal 
mammary nodes in the absence of clinically evident axillary node metastasis.   
N2a – Metastasis in ipsilateral axillary lymph nodes fixed to one another 
or to other structures 
N2b – Metastasis only in clinically apparent ipsilateral internal mammary 
nodes in the absence of clinically evident axillary lymph node metastasis.  
N3 – Metastasis to ipsilateral infraclavicular lymph node(s) with or without 
clinically evident axillary lymph nodes, or in clinically apparent ipsilateral internal 
mammary lymph node(s) and in the presence of clinically evident axillary lymph node 
metastasis, or metastasis in ipsilateral supraclavicular lymph nodes with or without 
axillary or internal mammary nodal involvement. 
N3a – Metastasis to ipsilateral infraclavicular lymph node(s) 
17 
 
N3b – Metastasis to ipsilateral internal mammary lymph node(s) and 
clinically apparent axillary lymph nodes 
N3c – Metastasis in ipsilateral supraclavicular lymph nodes with or 
without axillary or internal mammary nodal involvement 
 
B.2. Pathologic Classification 28,41,46 
Classification based on axillary lymph node dissection (ALND) with or without 
sentinel lymph node dissection (SLND). Classification based merely in SLND should 
be designated sn.  
NX – Regional lymph node cannot be assessed (they could be removed 
previously, or not removed, e.g.). 
NO - No regional lymph node metastasis. 
N1 – Metastasis to movable ipsilateral axillary lymph nodes. 
pNX – Regional lymph nodes cannot be assessed (e.g., previously removed, or 
not removed for pathologic study). 
pNO - No regional lymph node metastasis; no additional examination for 
isolated tumor cells (ITCs, defined as single tumor cells or small lusters not greater than 
0.2 mm, usually detected only by immunohistochemistry (IHC) or molecular methods 
but which may be verified on hematoxylin and eosin stains. ITCs do not usually show 
evidence of malignant activity [e.g., proliferation or stromal reaction]) 
pNO (i-) – No histological nodal metastasis, and negative by IHC 
pNO (i+) – No histological nodal metastasis but positive by IHC, with no 
cluster greater than 0.2 mm in diameter 
pNO (mol-) – No histological nodal metastasis and negative molecular 
findings (by reverse transcriptase polymerase chain reaction, RT-PCR) 
pNO (mol+) – No histological nodal metastasis, but positive molecular 
findings (by RT-PCR) 
 
pN1 – Metastasis in 1-3 ipsilateral axillary lymph node(s) and/or in internal 
mammary nodes with microscopic disease detected by SLND but not clinically apparent 
pN1mi – Metastasis (greater than 0.2 mm, none greater than 2.0mm) 
pN1a – Metastasis in 1-3 axillary lymph nodes 
pN1b – Metastasis to internal mammary lymph nodes with microscopic 
disease detected by SLND but not clinically apparent 
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pN1c – Metastasis in 1-3 ipsilateral axillary lymph node(s) and in 
internal mammary nodes with microscopic disease detected by SLND but not clinically 
apparent. If associated with more than three positive axillary nodes, the internal 
mammary nodes are classified as N3b to reflect increased tumor burden. 
pN2 – Metastasis in 4-9 axillary lymph nodes or in clinically apparent internal 
mammary lump nodes in the absence of axillary lymph nodes 
pN2a – Metastasis in 4-9 axillary lymph nodes (at least one tumor 
deposit >2 mm) 
pN2b – Metastasis in clinically apparent internal mammary lymph nodes 
in the absence of axillary nodes 
pN3 – Metastasis in 10 or more axillary lymph nodes, or in infraclavicular 
lymph nodes, or in clinically apparent ipsilateral internal mammary lymph nodes in the 
presence of one or more positive axillary nodes; or in more than three axillary lymph 
nodes with clinically negative microscopic metastasis in internal mammary lymph 
nodes; or in ipsilateral supraclavicular lymph node(s) 
pN3a – Metastasis in 10 or more axillary lymph nodes (at least one 
tumor deposit greater than 2.0 mm), or metastasis to the infraclavicular lymph nodes 
pN3b – Metastasis in clinically apparent ipsilateral internal mammary 
lymph nodes in the presence of one or more positive axillary nodes: or in more than 
three axillary lymph nodes detected by SLND but not clinically apparent 
pN3c – Metastasis in ipsilateral supraclavicular lymph node(s). 
 
 
C. Metastasis  
MX - Distant metastasis cannot be assessed. 
M0 – No distant metastasis 
M1 - Distant metastasis 
 
D. TNM stage grouping for breast cancer 
Cancer stage is a combination of T, N and M. Staging is usually confirmed after 
a surgery, but for neoadjuvant therapy
b
 staging is chiefly determined clinically. 
Physicians may use stage I to stage IIA to define early stages, and stages IIB to stage II 
                                                 
b
 Neoadjuvant therapy – treatment given before surgery.43 
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for locally advanced. Furthermore, it is imperative to retain the idea that tumor biology, 
like specific markers (e.g. estrogen receptors) have a huge impact on the advised 
treatment as well as in the prognosis. 
43
 
 
Table 1 | TMN stage grouping
c
 for breast cancer, as in the 7
th
Edition of AJCC Cancer 
Staging Manual (2010).
43,46
 (* – T1 includes T1mi) 
Stage  TNM N M 
Stage 0 Tis  NO MO 
Stage IA T1* NO MO 
Stage IB TO-
T1* 
N1mi MO 
Stage II A TO 
T1* 
T2 
N1 
N1 
N0 
MO 
MO 
MO 
Stage II B T2 
T3 
N1 
NO 
MO 
MO 
Stage III 
A  
TO 
T1* 
T2 
T3 
T3 
N2 
N2 
N2 
N1 
N2 
MO 
MO 
MO 
MO 
MO 
Stage III B T4 
T4 
T4 
N0 
N1 
N2 
MO 
MO 
MO 
Stage III C Any T N3 MO 
Stage IV Any T Any 
N 
M1 
  
Histopathologic Type 
Histological classification has been a valuable tool in past decades, and divide in 
situ carcinomas and invasive carcinomas;
41,47
 Relies on histology and put apart 
molecular markers that have a significant weight on prognosis.
47
 
 
Table 2 | Histopathologic classification of breast cancers - as in the 7thEdition of AJCC Cancer Staging 
Manual (2010)48 
Tumor Location Histologic subtype  
Carcinoma, NOS (Not otherwise 
specified) 
 
Ductal Intraductal (in situ) 
Invasive with predominant component 
                                                 
c
 TMN stage grouping used in TCGA (The Cancer Genome Atlas, a database used in the thesis) 
is from the7
th
 Edition of AJCC Cancer Staging Manual, in order to even out the results it was decided to 
place the 7th edition classification here; 6th edition can be found in Appendix table 1.  
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Invasive, NOS 
Comedo 
Inflammatory 
Medullary with lymphocytic infiltrate 
Mucinous (colloid) 
Papillary 
Scirrhous 
Tubular 
Other 
Lobular Invasive with predominant in situ 
component 
Invasive  
Nipple Paget disease, NOS 
Paget disease with intraductal carcinoma 
Paget disease with invasive ductal 
carcinoma 
Other  Undifferentiated carcinoma 
Metaplastic 
 
The following tumor subtypes occur in the breast but are not considered typical 
breast cancers: 
 Phyllodes tumor. 
 Angiosarcoma. 
 Primary lymphoma 
Types of tumor 
Commonly breast cancer is organized in subtypes, aiming the division in some 
(1) special receptors or in a (2) specific cluster of genes. 
1. Hormone receptors (routinely assays are performed by pathologists on 
tumor samples) 
28
 
a. Hormone receptor positive – Tumors express estrogen receptors 
(ER), progesterone receptors (PR),
44
 ER responsive genes and other 
genes that encode typical proteins of luminal epithelial cells.
49
 They 
may depend on hormones (estrogen and progesterone) to grow.
44
  
b. HER2 positive – Represents 20% - to 25% of breast cancers, these 
tumors are dependent of the gene HER2 (epidermal growth factor 
receptor 2) to grow and have a high abnormal number of HER2 
receptors or copies of the gene. 
44
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c. Triple negative – if the tumor do not express any of the previous 
hormone receptors (ER, PR and/or HER2). This type may grow faster 
than the hormone positive and be more sensitive to chemotherapy. 
44
 
2. Molecular classification of breast cancer subtypes 
Molecular classification was described first by Perou et al in 2000
50
, and 
gradually emerged as an answer to predict a response to targeted therapies and 
represents a high success in the design of individualized therapies in breast cancer, 
promoting an improvement in disease-specific survival.
51,52
Altough, studies show that 
combining both histological and molecular classifications result in significantly better 
predictive value. 
47,51
 After the first classification given by Perou et al (2000) several 
adjustments were made and now tumors are commonly classified into four major 
subtypes: luminal A, luminal B, HER2
+
 and basal like.
50–54
 This classification is a result 
of gene expression profiling given by “microarray datasets and progressed to a PCR-
based test with a curated list of 50 genes (the PAM50 gene signature).”54 Each subtype 
has a particular set of “risk factors for incidence, response to treatment, risk of disease 
progression and preferential organ sites of metastases.”51 
Luminal A – most common (50 to 60% of all BC); is characterized by an 
increase in estrogen receptor 1 (ESR1) and/or PR
+
/Her2
-
 status
47,53,55
 and lower levels of 
proliferation related genes, as Ki 67.
d
 
49,56
 It is also associated to low-grade tumors and 
good prognosis; 
47,53,55
 they will likely have a good response to hormonal treatments; 
with relapse rate lower than other subtypes. Recurrence is common in bone, but in 
tissues like liver, lung and central nervous system occur in a little less than 10% of 
patients. Include special histological types (tubular, invasive cribriform, mucinous and 
lobular).
51
 
 
Luminal B – Less common than luminal A (about 20% of all BC) although 
approximately 30% of HER2-positive tumors defined by IHC are assigned to the 
luminal B subtype. Demonstrate increase expression of growth receptor signaling genes 
and have a more aggressive
49
 phenotype with bad prognosis.
47,53
 
As an IHC point of view luminal B is defined by:  
 ER positive; HER2 negative; high Ki 67 or; 
 ER positive; HER2 positive.  
                                                 
d
 Ki 67 protein expression is strictly associated with cell proliferation,
104
 high levels are 
associated with worse outcomes
56
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But in fact, this definition does not englobe a small percentage (6%) of luminal 
B that are ER and HER negative. 
49,56
 
 
Note: 
Main difference between both luminal subgroups is increased expression of 
proliferation-related genes. Ki67 index is pointed as a potential marker to differentiate 
luminal A and B in clinical practice.
49
 Cheang et al (2009) stablished Ki67 index of 
14% or more Ki67-positive tumor nuclei as the best cut point.  
To summarize: Ki67 < 14% (low Ki67) – Luminal A 
 Ki67 ≥ 14% (high Ki67 – Luminal B 
However, Ki67 immunohistochemistry is not optimized and standardized as well 
the Ki67 cut off. 
49,56
 
 
HER 2
+
 – About 15-20% of BC. Characterized by high expression of HER2 
gene and other HER2 pathway related genes.
49
 
HER2 is a member of four membrane tyrosine kinases. “Upon ligand binding to 
their extracellular domains, HER proteins undergo dimerization and 
transphosphorylation of their extracellular domains.” Due to HER2 lack of ligand, 
HER2 relies on “heterodimerization with another family member or homodimerization 
with itself to be activated” at high levels. These “phosphorylated tyrosine residues 
interact with numerous intracellular signaling molecules” provoking downstream 
activation of second messenger pathways and crosstalk with other membrane signaling 
pathways, activating many genes involved in cell proliferation, differentiation, survival, 
angiogenesis, invasion and metastasis, 
49,57–60
 conferring more aggressive biological and 
clinical behavior. In the absence of treatment, HER2
+
 have a poor diagnosis and a 
susceptibility to metastasize to brain and visceral organs.
49
 
 
Basal-like – Low frequency (3-15% of all BC); frequently lack hormone 
receptors (e.g. ER and PR) and HER2, hence are called triple negative breast cancer 
(TNBC), but not all basal like are TNBC and not all TNBC are basal-like.
49
 Either 
characterized for the expression of keratin 5, 6 and 17, integrin beta, fatty acids and 
laminin.
50,51,53,61,62
 Currently there is “no molecular-based targeted therapies”51 and 
only 20% have a good response to standard chemotherapy, nevertheless numerous 
agents are in clinical trials that unfortunately seem to fail treating TNBC (as a result 
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have a poor outcome) further studies point to a subdivision of TNBC in five or six 
classes, with specific molecular features, that can explain the low response to drugs; 
51,63–65
  
Basal like cancers undergo frequent mutations in TP53
e
 (tumor protein 53) gene; 
approximately ¾ of basal-like tumors are BRCA1 (breast cancer 1). 
 
MGP – Matrix Gla Protein 
Matrix Gla Protein (MGP) was first isolated from urea extracts of demineralized 
bovine bone, being the second vitamin K-dependent (VKD)
f
 to be discovered in bone, 
after osteocalcin (also known BGP or bone Gla protein).
66,67
 Different tissues (e.g. 
heart, lung, kidney and breast) express MGP.
66,68,69
 
Human MGP has a single copy gene
66
 located in the small arm of chromosome 
12 (12p12.3) and encodes a 10-kD (kilo Dalton) skeletal extracellular matrix (ECM) 
protein.
70
  
MGP primary structure consists in a signal peptide, a phosphorylation domain 
and a γ-carboxylase recognition site. MGP has also five Gla residues (γ-carboxylated 
glutamic acid) (Figure 11),  which are converted by γ-glutamyl carboxylase enzyme 
(dependent of vitamin K
66,71,72
 – using it as a cofactor)70 through a posttranslational 
modification; this alteration gives high affinity for mineral and mineral ions
70,73,74
 like 
calcium, phosphate and hydroxyapatite crystals (mineral components of skeletal 
ECM).
70
 
 
MGP variants  
For several years MGP was known as a four exon gene (with a total of 1398  
base pairs [bp]) but recently a specific MGP variant was identified in human fetal tissue, 
with an insertion of a new protein domain, resulting in the synthesis of a longer protein 
                                                 
e
 TP53 – evidence of genomic instability and inactivation of the retinoblastoma (Rb) pathway.49 
f
 VKD proteins have several functions, including: hemostasis, apoptosis and growth control.
74
 
Figure 11 | Schematic representation of matrix Gla protein (MGP), pointing out the primary structure and Gla 
domains. 
Primary structure: Signal peptide – SP; Phosphorylation domain – P, in a green box (phosphoserine residues are 
represented by green dots; γ-carboxylase recognition site – γ, in a blue box.  
Gla residues: blue dot. Adapted from Cancela et al (2014) 
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isoform (with 1473bp). This novel isoform was labeled E5 (contain five exons) while 
the previous isoform was labeled E4 (contain four exons) (Figure 12). Isoform E5 have 
three putative additional sites of gamma carboxylation,
71,72
 this feature could increase 
MGP binding capacity, resulting in a more powerful inhibitory function.  
 
Alternative splicing 
Humans produce around 90 000 different proteins, and scientific community was 
expecting that human genome project would reveal a similar number of genes (“one 
gene to one protein”) so it was a huge surprise that the real number of genes is almost 
four times smaller than expected – about 25000 genes. Insights in this paradigm resulted 
in the concept of alternative splicing – a mechanism where a single gene is the origin of 
multiple proteins, tallying protein diversity.
75
 In average, one human gene has eight 
exons and seven introns, that gives rise in average to three or more alternatively spliced 
mRNA (messenger RNA). Recent high-throughput sequencing studies point that 100% 
of human genes produce at least two or three isoforms.
76
   
The first transcript of the gene is pre-messenger RNA (pre-mRNA) – copy of the 
gene including both introns (intended to be removed during pre-mRNA processing) and 
exons. In RNA splicing exons are retained and exons targeted for removal in order to 
create different mRNA from the same primordial information (pre-mRNA). The same 
nucleotide sequence can be an exon or an intron, depending on the splicing target.
77
 
 
Characterization of the protein and its functions 
Fraser and Price in 1988
69
 described MGP as the first well characterized 
substrate of VKD found in discrete tissue-specific cells (kidney, lung, heart and spleen 
Figure 12 | MGP schematic representation. Variant E5 (5 exons) and variant E4 (4exons) – novel isoform 
(E5) have one extra exon (75bp) due to alternative splicing in MGP gene. Exon at red (Ex2) is only present in 
isoform E5. 
Isoform E5  
Isoform E4  
Ex1 Ex2 Ex3 Ex4 Ex5 
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cells), showing that MGP function is beyond specific connective tissues, thus, is 
unlikely that MGP acts just for accumulation in an extracellular matrix.  
In 1997, Luo et al
73
 developed homozygous mice without Mgp expression 
(MGP
m1
/ MGP
m1
). Those mice until the second week were similar to control mice but 
then they became shorter and with a faster heart beat; within two months they died due 
hemorrhage triggered by thoracic or abdominal aortic rupture, showing signals of 
prominent calcification.  Findings suggested: 
 Mgp inhibits calcification of certain ECMs, probably as a result of its 
capacity of mineral-ion-binding. 
 In early development other gene products play an important role to 
prevent earlier calcification, otherwise newborn or one-week-old 
MGPm
1
/ MGP
m1 
mice must have showed defects. 
73
 
Studies show also the involvement of MGP in cell differentiation
71,78
 and 
proliferation.
71,72
 
Mutations (with loss of function) in this gene were related with: atherosclerosis 
(vascular calcification), cancer
68,79,80
 and were proven to lead Keutel syndrome whom is 
characterized by abnormal formation of cartilage calcifications (in auricles, nose, 
larynxes, trachea and ribs), multiple peripheral pulmonary stenosis, neural hearing loss 
and short terminal phalanges. 
70
  
 
MGP and cancer  
As stated above, MGP was showed a role in cell differentiation and 
proliferation, and was suggested a role also in cell migration, differentiation, onset of 
angiogenesis
81
 and tumorigenesis.
72,82,83
 However, MGP role in oncogenesis is unclear 
as well as the correlation between its expression and tumor type.
68
 Some studies were 
performed and in some tumor types expression was higher and in other types lower than 
in normal tissue, giving in some cases prognostic value. 
Regarding MGP mRNA expression analyses we can see: 
Ovarian cancer – MGP mRNA expression in tumor was higher 
compared to normal tissue. 
68,84
  
Renal cell carcinoma – higher expression in tumor tissue with a 
significant inverse correlation between mRNA expression and tumor size, lymph 
node metastasis and grade.
68,85
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Colorectal cancer – Fan et al (2001) 86 found a down-regulation of MGP 
mRNA in human adenocarcinomas but results obtained in our laboratory 
comparing cancer tissue and paired adjacent normal tissue showed an up-
regulation.
71
 
Astrocytic gliomas (AG) – comparing high and low grade AG, mRNA 
levels were significantly increased in high-grade tumors. 
68,83
 
 
Regarding protein expression, The Human Protein Atlas
87
 stained twenty 
different types of cancers and controls, the results (Table 3) in brief, show that 
malignant cells exhibited moderate to strong cytoplasmic and nuclear staining. Samples 
vary from 4 to 12, and the most exciting result regard MGP protein expression is in 
gliomas and liver cancers, where it could be observed a small upregulation of MGP 
relatively to normal tissue. Analyses of more samples could give more reliable results. 
 
 
MGP and Breast Cancer  
A study using cDNA hybridization revealed that MGP expression in breast 
cancer is 20-fold higher in metastatic cancer (cell line 600PEI) than in normal 
epithelium, 
68,88
 and Yoshimura et al (2009) presented MGP mRNA expression as a 
potential prognostic factor in BC patients, being overexpressed in poor prognostic 
patients (using microarray analyses). However, immunohistostaining of breast tissue 
microarrays did not revealed a correlation between overall survival or ER status 
metastasis with protein expression,
68
 this information is also supported by results in 
Table 3, where MGP is highly to medium expressed  in cancer staining and normal 
tissue is also highly expressed. 
 
Table 3 | MGP protein expression in tumoral vs normal tissue staining. Colors represent different levels of 
antibody/staining expression per sample. Adapted from The Human Protein Atlas.  
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Cell culture 
Is unethical starting research in humans or other animals before testing it before, 
for this reason a variety of models were and are being developed. For instance, cancer 
cell lines which are used currently in several biomedical research laboratories.
89,90
 
Cell lines are obtained by primary cultures (growing cells from tissue taken 
directly from an individual growing in a flask or petri dish. They provide an almost 
unlimited supply of cells (with similar genotypes and phenotypes). There are various 
observations that reveals cell lines as a good model for cancer research, as a first 
approach, for instance:
90
 
Histopathology: most human cancer cell lines transplanted to 
immunedeficient mice lead to tumors; histopathologic analysis of 127 human 
cell lines that formed tumors in mice reveled that they are all correlated with 
tumor origin. 
90
 
Molecular genetics and receptor expression: comparison between lung 
cancer and breast cancer cell line with origin cancers revealed that phenotypic 
(as ER receptors expression) and genotypic properties are retained for long 
periods of time. 
90
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Aims  
More and more cancer research is focused on target therapies and biomarkers. 
This kind of approach is imperative to refine strategies of screening and diagnosis 
leading to early detection, that is correlated with better prognosis. Furthermore, target 
therapies are known as less toxic and with reduce side effects, improving the wellbeing 
of cancer patients. To improve this approach is necessary to enlighten the role of genes 
related with tumorigenesis. Knowing that MGP role in breast cancer (and cancer in 
general) is unclear, our biggest aim is to try to clarify it, searching for correlations 
between its expression in normal vs tumoral samples of breast cancer, as well as in 
particular subsets of patients. Alongside our main aims were either: 
Clarify isoforms expression in breast cancer cell lines, as well as the result of 
isoforms overexpression in cellular proliferation and migration.  
Identify some regulatory mechanisms of MGP expression, in particular 
epigenetic (methylation) and posttranscriptional regulation (mir155 analyze, even as, its 
correlation in normal and tumoral tissue.  
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Cell lines and cultures 
It was used eight cell lines from human breast cancer tissue; those, five were 
commercial lines
91
 and three were primary cultures obtained from patient samples from 
CUF. Cells were maintained in the appropriate cell culture medium according to their 
specific requirements, as seen Table 4. 
 
Table 4 | Cell lines characterization and culture medium conditions; RPMI (Roswell Park Memorial Institute; Gibco, 
Life Technologies) 1640 Medium GlutaMAX; DMEM (Dulbecco’s Modified Eagle Medium; Gibco, Life 
Technologies); P/S – Pen Strep (Penicillin/Steptomycin mixture, Life Technologies); FBS (fetal bovine serum, Sigma 
Aldrich) 
 
All cell lines were maintained at 37ºC (Celsius degrees) and at 5% CO2 (carbon 
dioxide) and subdivided 1:2 three times a week, except TNBC-1 that was subdivided 
one to two times a week. BC cells were obtained already in a pellet for downstream 
applications.  
 
RNA extraction and purification  
Extraction and purification of total RNA was performed with GeneJET RNA 
Purfication Kit (ThermoScientific)
92
, according to manufacturer’s instructions.  
Suspension and adherent cells have different needs in sample preparation for 
pelleting, thus: 
Cell line Gender Age Disease Cell type Culture 
Medium 
FBS 
(%) 
Glutamine 
(%) 
P/S 
(%) 
C
o
m
m
er
ci
al
 
ZR-75-01 Female 63 Ductal 
carninoma 
Epithelial RPMI 1640 
GlutaMAX 
10 0 1 
MDA-
MB-231 
Female 51 Adenocarcinoma Epithelial DMEM 10 1 1 
MCF-7 Female 69 Adenocarcinoma Epithelial DMEM 10 1 1 
T47D Female 54 Ductal 
carninoma 
Epithelial DMEM 10 1 1 
HCC1428 Female 49 TNM stage IV, 
grade 4, 
adenocarcinoma 
Epithelial DMEM 10 1 1 
P
ri
m
ar
y 
cu
lt
u
re
 CFI-TERT Female    DMEM 20 1 1 
TNBC-1 Female 39   DMEM 20 1 1 
BC  Female 64 Cell pellet 
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 Up to 1x107 cells in suspension were collected in culture medium and 
centrifuged for 5 minutes at 250 x g. After discarding the supernatant, the 
cells were rinsed with PBS and centrifuged again to remove residual 
growth medium.  
 Culture medium from adherent cells was removed and cells were rinsed 
with PBS to assure total removal of residual medium. Washing PBS was 
discarded and an additional 1mL of PBS was added to the petri plate, 
cells were detached using a scraper and transferred into a 1.5mL 
microcentrifuge tube and pellet by centrifugation (5 minutes at 250 x g). 
In both cases after discarding the supernatant the pellet was used do extract RNA 
or stored at -70ºC until use. 
Pellets were resuspended in 600 µL of Lysis Buffer supplemented with β-
mercaptoethanol, (the mixture presents a detergent basis use to break lipid barriers in 
cells
93
, exposing genetic information; solution contains also guanidine thiocyanate – 
(chaotropic) salt capable of cell lysis and protecting RNA from endogenous 
RNases[RNA nucleases] ) and vortexed for 10 seconds to mix. The lysates were 
homogenized passing the mixture into a blunt 20-gauge needle fitted to an RNase-free 
syringe several times. This step is important because an incomplete homogenization 
results in a significant reduction of RNA yields.   
After adding 360 µL off ethanol (96%-100%) (to precipitate RNA
94
) and mixing 
by pipetting, up to 700 µL of the lysate/mixture was transferred to a GeneJET RNA 
Purification Column
g
 (inserted in a collection tube) and centrifuged for 1 minute at 
≥12000 x g. The flow-through was discarded. This process was repeated till all the 
lysate was processed in the column and centrifuged; at the end the collection tube was 
changed. Then 700 µL of Wash Buffer 1 was added to the Column and centrifuged for 
1minute at ≥12000 × g, the flow-through was discarded and 600 µL of Wash Buffer 2 
was added and centrifuge and discard step were repeated. An additional volume of 250 
µL of Wash Buffer 2 was added and centrifuged for 2 minutes at ≥12000 × g. After 
discarding the flow –through one plus step of centrifugation were performed at 
maximum speed for 1 minute to guarantee that all the residual solution was discarded. 
The final step – RNA elution was performed placing the column in a 1.5mL RNase-free 
microcentrifuge tube and adding 50 µL of sterile water (Sigma) in the center of the 
                                                 
g
 GeneJET RNA Purification Column – with a sílica-based membrane technology that presents 
acid-bindings properties in the presence of guanidine thiocyanate. 
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column, after one final centrifugation at ≥12000 × g for 1 minute the column was 
discarded and purified RNA was used or stored at -20ºC or -70ºC until use.  
Quality and quantity of RNA was assessed by spectrophotometry (Nanodrop 
ND-1000, Thermo Scientific), through reading the absorbance of each sample at 230, 
260 and 280 nm, and determining the ratios at 260/230 nm and 260/280 nm.  
 
Synthesis of cDNA by Reverse Transcriptase reaction 
Total RNA (1 µg) was treated with RQ1 DNase (1U for each 1 µg of RNA: 
Promega), 1 µL of 1x RQ1 DNase Buffer (10x, Promega) and water (Sigma) till the 
final volume of 10 µL, according to manufacturer’s instructions. After incubation (30 
minutes at 37ºC) the reaction was stopped by adding 1 µL RQ1 DNase Stop Solution 
(1U for each 1 µg of RNA, Promega) and incubating for 10 minutes at 65ºC. This step 
uses a endonuclease (DNase I) to degrade double and single-stranded DNA assuring the 
integrity of RNA. 
RNA samples after the DNase treatment were reverse transcribed into cDNA 
using Moloney-murine leukemia virus (M-MLV) reverse transcriptase (200U/µL).  For 
that, it was added to RNA samples: 
 4 µL (1x) First Strand (FS) Buffer (5x FS Buffer, Invitrogen); 
 1 µL DTT, (0.1M, Invitrogen); 
 1 µL oligo dT primer (10µM, Invitrogen);  
 1 µL dNTPs (10mM each [dATP, dTTP, dCTP, dGTP]). 
Then the mixture stayed for 5 minutes at 4ºC and were supplemented with 
 1 µL of RNase Out (40U/µL, Invitrogen) – incubated at 37ºC, 2 minutes. 
 1 µL M-MLV – incubates at 37ºC for 50 minutes and to inactivate the 
reaction incubated at 70ºC for 15 minutes. 
The cDNA can at this point be used as a template for PCR or qRT-PCR or stored 
at -20ºC. 
 
qRT-PCR – Quantitative Real Time – Polymerase Chain Reaction 
cDNA samples obtained by reverse transcriptase reaction were used as templates 
for real-time quantitative polymerase chain reaction (qRT-PCR) for analyze the 
expression of MGP mRNA, using specific set of primers (Appendix table 4). 
Incubated at 
65ºC, 5 minutes 
 
Incubated at 
65ºC, 5 minutes 
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PCR amplification was placed in a 96-well PCR micro-plate (Thermo 
Scientific); where 2 µL of cDNA (diluted 1/10) was mixed with 10µL of SsoFast™ Eva 
Green Mix (BioRad), 0.6 µL of each forward and reverse primers (10 µM) and 6.8 µL 
(to a final volume of 20 µL). Micro-plates were sealed with adhesive PCR film (Thermo 
Scientific) and amplifications were performed in a CFX96™ Real-Time PCR Detection 
System (BioRad) under the following conditions: denaturation and polymerase 
activation at 95ºC for 30 seconds; 40 cycles of denaturation (5 seconds at 95ºC) and 
annealing/elongation (30 seconds at 57ºC); melt curve (65ºC to 95ºC, incrementing 
0.5ºC) for determination of melting point.  
As a negative control PCR amplifications were performed with sterile water; a 
relative expression was determined using 2
-ΔΔCt method95. Threshold cycles obtained for 
each variant were normalized using a housekeeping geneh GAPDH (Glyceraldehyde-3-
phosphate Dehydrogenase) and the expression of MCF-7 cell line which previous work in 
the lab confirmed the presence of the two isoforms.  
 
Confirming results of qRT-PCR by Electrophoresis and Sequencing  
Electrophoresis is the standard protocol to separate DNA by size, and was 
performed in the products of qRT-PCR, to confirm the presence of different isoforms 
(with different DNA fragments). Samples were loaded on a 1.5% agarose gel containing 
Green Safe Premium (NZY Tech) intercalating dye and run with 1x TAE (Tris-Acetate-
EDTA) buffer at 120 Volts (V) for 15-20 minutes. The fragments were visualized under 
UV light. 
PCR products with the expected size were removed with a sterile blade and 
DNA was purified using GeneJET Gel Extraction Kit (Thermo Scientific) according 
manufacturer’s instructions; the technique underlie under the principle that in high 
temperatures (50ºC to 60ºC) the agarose gel melt; using binding properties of DNA to 
the silica based column and washing buffers proteins and contaminants are removed and 
DNA is purified and diluted in sterile water. A sample of the purified DNA and specific 
primers was sent to sequencing evaluation at CCMAR facilities. 
 
                                                 
h
 Housekeeping genes – they encode “proteins that are required universally to maintain viability 
of all cell types throughout the body or to carry out certain biological functions common to all cell 
types.”5 
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Transient transfection  
Cells were transfected with EzWay™ Transfection Reagent (Koma Biotech inc.) 
– a cationic lipid with DNA binding affinity. 
The day before the transfection cells were plated to rich 80 – 90% of confluency 
in the next day – previous tests were made with a differential number of cells to assess 
best transfection conditions; transient transfections were performed in TNBC cells and 
CFI-TERT. Per each well the transfection solution was added drop by drop and was 
prepared according to the manufacturing instructions. For 24 well plate (3x10
4
 
cells/well): 0.8 µg of DNA was diluted in 50 µL of Opti-Mem (Gibco, Life 
technologies, ThermoFisher); 1 µL of reagent diluted in 50 µL of Opti-Mem; both 
solutions were combined gently and incubated for 30 minutes at room temperature, to 
allow liposome-DNA complexes to form; and then 100 µL of the complex was added 
per well. In 96 well plate the protocol was the same, but were placed a smaller number 
of cells (1.5x10
4
 cells/well) and DNA (3.5 µg). As a negative control were used wells 
without transfection reagents and as a positive control an empty plasmid (pcDNA). 
Plasmids tested contained E4 and E5 isoforms (work done previously in the lab).  
 
Cell Viability Assays 
XTT (tetrazolium salt, AppliChem) was performed to assay viability of wild 
type (WT) cells in comparison to transfected cells with E4 and E5 variants. 
Live cells can reduce tetrazolium salts into colored (orange) formazan 
compounds through mitochondrial enzymes, which are inactivated after death. The dye 
(water soluble) intensity can be measured (wavelength) in a spectrophotometer 
(microplate reader Synergy 4). It was performed a XTT optimization protocol to 
evaluate the optimal incubation time of the reagent, and hourly measurements were 
performed at 450nm and 690 nm (for background corrections) after adding XTT to cells 
as described by the manufacturer – it was determined an optimal incubation time of 4h. 
Right after transfection it was added 50 µL of XTT mixture to each well (ratio for XTT 
preparation was 1 µL of activation solution to 50 µL of XTT reagent). XTT 
measurements were performed at time 0h (zero) – 4h after transient transfection; 24h, 
48h and 72h. Blank measurements (triplicates) were performed in wells containing only 
growing medium and XTT and the average absorbance at 450nm was subtracted to 
specifics results.  
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Specific absorbance was defined by subtracting results of absorbance at 690nm 
for results of 450nm absorbance. 
 
Wound healing assay – motility assay  
Wound healing assay is used to assess 
cell migration. 3x10
4
 of CFI-TERT cells were 
plated in 24 well plate and transfection assay 
were performed as described before. When 
cells reached about 90% of confluency the 
bottom of each well was scratched using a 
sterile tip (1000 µL) (Figure 13), the scratch is 
used to mimic a wound, and should be 
possible visualize the two edges using a 
magnification of 100 times. At least 3 
photographs (Canon PowerShot G12) were 
taken of each condition (with replicates) at 0h, 
24h, 48h, 72h and 96h. After the scratch and before taken pictures the wells were rinsed 
two times with PBS. At the end was calculated the percentage of invaded area. 
 
 Demethylating treatment with 5 – Azacytidine  
5-Azacytidine (5Aza) (Sigma Aldrich) is a pyrimidine ring analog of cytidine, 
that inhibit enzymes that methylate cytosine residues in eukaryotic DNA, altering 
methylation status and activating genes that other way were inactivated by methylation. 
Because of its cytotoxic effect additional safety procedures were taken. 
 5Aza was dissolved in PBS (1x – phosphate buffered saline) to a 5mM 
concentration and then it was added to T47D cells in a 6 well plate (plated with 6x10
5
 
cells in the previous day). The treatment was repeated after 24h and 48h; and after 72h 
RNA and DNA extraction was performed. As a negative control it was added only PBS 
(without treatment) to the cells. 5Aza is very unstable in aqueous solutions, so fresh 
solutions were made every treatment day.  
 
Figure 13 | Wound healing assay draft 
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Genomic DNA extraction from culture cells  
Genomic DNA was extracted using DNeasy Blood & Tissue kit (Qiagen). The 
kit is based in a buffer system optimized to allow direct cell lysis (by proteinase K) 
followed by selective binding of DNA to the DNeasy membrane (due to high 
concentration of chaotropic salt, that removes water from hydrated molecules in 
solution). Centrifugation process and buffer condition are used for completely remove 
contaminants and enzymes inhibitors like proteins. 
Culture medium was removed and cells were rinsed with PBS to assure total 
removal of residual medium. Washing PBS was discarded and an additional volume of 
appropriate PBS was added to each well, cells were detached using a scraper and 
transferred into a 1.5 mL microcentrifuge tube and pellet by centrifugation (5minutes at 
300 x g); pellet was then ressuspended in 200 µL PBS and 20 µL of proteinase K was 
added; as well 200 µL of Buffer AL (mixed by vortex), the homogeneous mixture was 
then incubated at 56ºC for 10 minutes; afterward was added 200 µL of ethanol (96-
100%) and the mixture was mix through vortex; at this point solution was pipetted to a 
DNeasy Mini spin column and was centrifuged at  ≥6000 x g per 1 minute; the flow-
through was discarded as well the 2 mL collection tube, that was replaced for a new 
one; 500 µL of buffer AW1 was added and centrifuged again for 1 minute at ≥6000 x g; 
the flow-through was discarded as well the collection tube and an additional volume of 
500 µL of buffer  AW2 was  added and centrifuged for 3 minutes at 20000 x g, to dry 
the DNeasy membrane, to guarantee that residual ethanol was not present, once it could 
interfere with succeeding reactions; the spin column was placed in a 1.5 mL 
microcentifuge tube and 100 µL sterile water (Sigma Aldrich) was added; an incubation 
time of 1 minute at room temperature was performed before the last centrifugation for 1 
minute at  ≥6000 x g.  
Quality and quantity of DNA was assessed by spectrophotometry (Nanodrop 
ND-1000, Thermo Scientific), through reading the absorbance of each sample at 230, 
260 and 280 nm, and determining the ratios at 260/230 nm and 260/280 nm.  
 
Methylation analysis by bisulfite conversion 
Sodium bisulfite conversion is the standard method for methylation analyses. 
The DNA methylation, that usually occur in CpG dinucleotides, modify cytosines into 
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5-methylcytosines (5-mC), and the outcome of incubation of target DNA with sodium 
bisulfite is the conversion of unmodified cytosines into uracils (5-mC stay intact).  
Sodium bisulfite conversion was performed on genomic DNA, extracted from 
cells as described above, using the EpiMark Bisulfite Conversion kit (New England 
Biolabs Inc). Briefly, in a 0.2 mL PCR tube it was gently mixed by pipetting 1 µg of 
genomic DNA and sterile water (Sigma Aldrich) – up to 10 µL – and 130 µL of 
bisulfite mix; mixture was then transferred to a thermocycler (Biometra) under the 
following conditions on Table 5.  
 
Table 5 | Cycling protocol for bisulfite conversion reaction.  
Cycle Step Temperature Time (minutes) 
Denaturation 95ºC 5 
Incubation 65 ºC 30 
Denaturation 95 ºC 5 
Incubation 65 ºC 60 
Denaturation 95 ºC 5 
Incubation 65 ºC 90 
Hold 18 – 20 ºC Up to 12 hours 
 
The next step was the desulphonation and clean-up of the converted DNA that 
was accomplished by transferring the individual reactions into 1.5 mL microcentrifuge 
tubes and adding 550 µL of DNA Binding Buffer. After mix it briefly, the sample was 
them loaded in an EpiMark spin column with a 2 mL collection tube and centrifuged for 
1 minute at 15000 x g. The flow-through was discarded and 500 µL of Wash Buffer was 
added, the centrifugation step was repeated, the flow-through discarded, and 500 µL of 
Desulphonation Reaction Buffer was added and the mixture was left incubating at room 
temperature for 15 minutes.  Afterwards the centrifugation step was repeated; two wash 
steps were performed adding 500 µL of Wash Buffer followed by the centrifugation 
step; the spin column was putted into a sterile 1.5 mL microcentrifuge tube and 20 µL 
of sterile water (Sigma) was incubated for one minute at room temperature and a last 
centrifugation step was performed. DNA eluted was then analyzed by PCR.  
CpG islands upstream of the MGP gene were identified based on information in 
the UCSC genome browser (https://genome.ucsc.edu). Primers to amplify an upstream 
CpG island were designed with MethPrimer software 
(http://www.urogene.org/methprimer) which amplified a region containing one CpG. 
PCR analyze was performed with two different Taq DNA polymerase (Kapa 
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Biosystems polymerase kit and Invitrogen kit), according manufacturer’s instructions, 
as described in Table 6. The PCR products were run on a 1.5% agarose gel containing 
Green Safe Premium (NZY Tech) dye at 120V V for 15 – 20 minutes. Resulting DNA 
fragments of the expected size were purified using the GeneJET Gel Extraction Kit 
(Thermo Scientific) according manufacturer’s instructions and sequenced at CCMAR 
facilities and methylation status of the CpG was assessed. 
 
Table 6 | PCR conditions using two different Taq polymerase, in particular Kapa Biosystems kit and Invitrogen Kit. 
PCR component – Kapa 
Biosystems 
PCR Run 
Reagents 
25 µL 
reaction 
Step 
Temperature 
(ºC) 
Duration Cycles 
5x KAPA 
HiFi buffer 
5 µL 
Initial 
denaturation 
95 30 s 1 
Denaturation 95 15s 
40 
10 mM 
dNTPs 
0.5 µL Annealing 55 30 s 
10 µM 
Forward 
Primer 
0.5 µL Extension 68 1 min. 
10 µM 
Reverse 
Primer 
0.5 µL 
Final 
extension 
68 5 min 1 
Genomic 
DNA 
6 µL 
Hold 4 Indefinitely 
KAPA HiFi 
HotStart 
DNA 
Polymerase 
1 µL 
Sterile 
water 
11.5 µL 
 
PCR component – 
Invitrogen 
PCR run 
Reagents 
50 µL 
reaction 
Step 
Temperature 
(ºC) 
Duration Cycles 
10x PCR 
bufffer 
5µL 
Initial 
denaturation 
94 3 min. 1 
50mM MgCl2 1,5 µL Denaturation 94 45 s 
40 
10 mM 
dNTPs 
1 µL Annealing 55 30 s 
10 µM 
Forward 
primer 
2.5 µL Extension 72 90 s 
10 µM 
Reverse 
2.5 µL 
Final 
extension 
72 10 min 1 
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Primer 
Genomic 
DNA 
6 µL 
Hold 4 Indefinitely 
KAPA HiFi 
HotStart 
DNA 
Polymerase 
0.25 µL 
Sterile water 
31.25 
µL 
 
Bioinformatic database – The Cancer Genome Atlas (TCGA) 
The Cancer Genome Atlas (TCGA) is the outcome of a collaboration between 
The National Cancer Institute’s (NIH) and the National Human Genome Research 
Institute (NHGRI). Is a platform of sharing data that includes multi-dimensional maps 
of the key genomic changes in 33 types of cancer. The data is collected by tumor tissue 
and matched normal tissue. In particular, breast cancer is referred as BRCA (Breast 
invasive Carcinoma), and more than one thousand samples are available for analyze. 
 
Patients selection  
Using Cancer Genomics Browser (University of California in Santa Crus, USA) 
and cBioPortal (Memorial Sloan Kettering – Cancer Center) we were able to download 
selected information for every sample; then we select patients with matched samples for 
tumoral and normal tissue
i
. Selected samples are from women – only one man matched 
sample was available, and was excluded because it would not be statistical relevant); for 
the same reason one sample from one Asian woman was excluded. Information was 
organized in an Excel sheet (Microsoft Office, 2016) and analyzed with SPSS (IBM 
Analytics) and GraphPad Prism 6 (GraphPad software, Inc.). Selected information can 
be seen in Appendix table 5.  
 
  
                                                 
i
 Normal Tissue – samples were collected from adjacent tissue of the tumor. 
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Chapter III – Results and Discussion  
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MGP expression in different cell lines  
Several breast cancer cell lines were analyzed to assess the presence of the two 
known variants of MGP – E4 and E5. First, it was performed a qRT-PCR, and then the 
results were confirmed by electrophoresis and sequencing. The set of primers used to 
assess expression of: 
– E5 isoform was F1 (drawn in exon 1) and R4 (drawn in exon 2 – exclusively 
of E5 variant).  
– E4 isoform was F1 and F5 (drawn in exon 5) (Figure 14).  
As shown before, qRT-PCR results were normalized using 2
-∆∆Ct
. Expression results 
obtained are a comparison between the several cell lines tested and MCF-7, which 
expression values are equal to one (Figure 15).  
 
 
 
 
 
 
 
 
 
 
At first sight E5 seem to be expressed in every cell line and E4 seem be 
expressed in low quantity or absent in CFI-TERT; MDA-MB-231 and in BC. To 
confirm results from qRT-PCR an electrophoresis assay was performed and the bands 
were extracted and undergo sequencing was possible to verify the presence or absence 
of the two isoforms in each cell line. 
Cell line 
E5 E4 
Mean 
Standard 
deviation 
Mean 
Standard 
deviation 
MCF-7 1.00 ±0.08 1.00 ±0.08 
ZR-75-01 1.53 ±0.96 7.41 ±2.55 
CFI-
TERT 
0.29 ±0.51 0.00 ±0.00 
T47D 10.97 ±3.95 87.73 ±8.77 
HCC1954 0.23 ±0.16 1.66 ±0.40 
MDA-
MB-231 
0.42 ±0.10 0.00 ±0.00 
TNBC-1 0.63 ±0.00 0.81 ±0.15 
BC 2.90 ±0.08 0.15 ±0.06 
F1 R4 
F1 R5 
Figure 14 | Primers localization in MGP gene. The red band represents Forward 1 (F1) primer, in exon 1; orange 
band represents Reverse 5 (R5) primer, in exon 5 (used to identify isoform E4 with F1); and blue band represents 
Reverse 4 (R4) primer, in exon 2 (used to identify isoform E5). 
Figure 15 | Relative expression of E4 and E5 MGP isoforms in several breast cancer cell lines. Expression was 
obtained from qRT-PCR – normalized using 2-∆∆Ct method relative to GAPDH (housekeeping gene) and MCF-7.  
1 
A B 
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Electrophoresis showed very different results than qRT-PCR. Isoform E4 is 
present in every cell line and E5 appears to be present in ZR-75-01 and T47D and 
maybe in CFI-TERT (Figure 16). 
 
 
 
 
 
Due to the disparity in qRT-PCR and electrophoresis assay sequencing was 
essential to confirm the results (Figure 17). We could conclude that on fact E4 is 
expressed in every cell line and E5 seems to be expressed only in ZR-75-01; T47D and 
HCC1954 cell lines.  
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
ZR-75-01 T47D HCC1954 
Exon 1 Exon 2 Exon 1 Exon 2 Exon 1 Exon 2 
Exon 1 Exon 3 Exon 1 Exon 3 Exon 1 Exon 3 
Exon 1 Exon 3 Exon 1 Exon 3 
Exon 1 Exon 3 Exon 1 Exon 3 
MDA-MB-231 CFI-TERT 
TNBC BC 
 ZR-75-01 CFI- BC HCC1954  TNBC-1 MDA-MB-231  T47D 
Figure 16 | Electrophoresis assay suggesting the presence of E4 in all cell lines and the presence of E5 only in ZR-
75-01, CFI-TERT, T47D and HCC195 (a light band appeared, although is not visible in the picture).  
 E4          E5           E4         E5           E4        E5        E4        E5          E4          E5         E4          E5        E4         E5    
500bp 
Figure 17 | Chromatograms from sequencing revealed that E4 is present in every cell line and confirmed the presence 
oE5 only in ZR-75-01, T47D and HCC1954 cell lines. (Images obtained using Geneious, Biomatters Limited) 
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Figure 18 | XTT assay to determine optimal incubation time of the reagent in: A) CFI-TERT and B) TNBC cell lines.  
Even though preliminary results derived from qRT-PCR suggested the E5 
expression in BC cell line it was not possible to detect a band in electrophorese neither 
sequencing. 
From the three techniques, sequencing is the more reliable, thus, although the 
disparity of the results, is secure to say that E4 expression is certain in all cell lines and 
E5 expression is certain in only three cell lines. qRT-PCR were performed in machines 
that we later found out were not working well, in a certain way the disparity of results 
could be explained because of that.  
Specificity of primers could be an explanation either. However, several set of 
primers were used to assess the isoforms expression and the set F1+R4 and F1+R5 
showed to be the more reliable. In spite of the fact that F1+R5 in theory is not specific 
for E4 isoform, sequencing results showed only the expression of E4, either in this 
analysis as in others performed previous in our lab.  
 
Proliferation and Migration Assays  
XTT – CFI-TERT and TNBC 
An evaluation of the optimal incubation time of the reagent was determined by 
hourly measurements and was established in 4h for both cell lines (CFI-TERT and 
TNBC).  
As a control we used WT (wild type – cells not transfected) and cells transfected 
with an empty vector, to exclude faux variations derived from the transfection assay. 
We expected to see that both WT and cells transfected with the empty vector proliferate 
similarly.  
A B 
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A 
Figure 19  | XTT assay in A) CFI-TERT and B) TNBC cell lines. 
B 
In CFI-TERT cell line (Figure 19A), transfected cells present a similar behavior, 
very different from the WT, suggesting that the variation observed is due to the effect of 
transfection. In TNBC (Figure 19B) cells, at initial time zero (four hours after the 
transfection and XTT protocol) we see a big variation, and then a similar behavior is 
seen; to evaluate if it is a result of the transfection, or human error, it is necessary to 
repeat the treatment. 
 
Both cell lines are not commercial, they are more sensitive in specially TNBC 
cells that have a low growth rate and are easily contaminated. In the second assay 
TNBC cells got contaminated. XTT treatment was performed in the same plate, for that 
reason a cross contamination of CFI-TERT could had occur although no evidence was 
seen, and could alter the results. Additional repetitions were not performed because of 
time – to rich the necessary number of cells to perform this assay cells must be in 
culture in average three to four weeks and then XTT protocol is performed (requiring 
one additional week) – if a contamination occur is necessary return to point zero and 
defrost a new batch, impairing the task. 
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Figure 21 | Invaded área after 24h, 48, 72h and 96 hours in diferente conditions (WT, 
empty vector, E5 and E4). 
Wound healing assay  
This assay was performed in CFI-TERT cells, to evaluate cell migration under 
overexpression of each isoform during 96h. Percentage of invaded area was calculated 
using the average value of replicates for each condition, at time zero. Results are shown 
in Figure 20 and Figure 21. 
 
 
 
 
 
 
 
 
 
 
 
 
Comparing WT and cells transfected with an empty vector, results are similar, as 
expected. When comparing cells with overexpression of E5 or E4 to WT was possible 
to observe a reduction of area invaded, revealing an already described paper in cell 
migration of MGP)  
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Figure 20 | Wound healing assay over 96h in CFI-TERT cells – WT, transfected with an empty vector or E5, or E4. 
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Methylation analysis   
After 5-Aza treatment was performed a bisulfite conversion, where occurs the 
conversion of unmodified cytosines into uracils (5-mC stay intact), with in mind this, 
two set of primers were made (F1/R1 and F2/R2) to identify the absence or presence of 
methylation status. As a control it was used the T47D cells without 5-aza treatment. 
After the PCR, an electrophoretic assay 
was performed and only in F1/R1 control (CTL) 
did not appear one band (Figure 22). Bands were 
extracted and undergo sequencing but without 
no results. Even after altering Taq polymerase 
and conditions of PCR, it was not possible to 
obtain sequencing results. The expected size of 
the band was different from the ones obtained, 
this made us wondering about primer specificity. 
Furthermore, in one bisulfite conversion of 
gDNA, occurred a formation of a precipitate, leading us doubting the integrity of the kit. 
In summary, the experiment was not conclusive and need more optimization. 
 
Analysis breast cancer genomics data using the cBioPortal 
In the absence of envisaged fresh samples of breast cancer tissue to evaluate the 
levels of MGP mRNA expression, in cancer vs normal 
tissue, an in silico approach was used, using 
international TCGA database (breast cancer samples 
are labeled as BRCA). At a first sight, using a heatmap 
(https://genome-cancer.ucsc.edu/proj/site/hgHeatmap/ 
– Figure 23) of MGP expression was possible to 
observe that there is a difference in gene expression 
between normal and tumoral tissue, so we further 
analyzed this data.   
At this point, it was important to select a 
population to assess statistical information from the 
dataset; using only matched samples of the same 
patient for normal (tissue collected from an adjacent 
Figure 23 | Heatmap of MGP expression 
in BRCA samples, presenting a 
possibility of differential expression in 
normal vs tumoral tissue. (T) represents 
data from tumoral tissue (blue) and (N) 
represents normal tissue (pink). Data was 
normalized subtracting the mean of gene 
expression from each sample (data values 
in blue represent gene expression less 
than zero; in red more than zero and in 
white equal to zero – mean). Adapted 
from Genome Browser Cancer.  
Figure 22 | Electrophoretic assay of PCR samples 
after bisulfite treatment. Control samples are 
refered as (Ctr) and samples treated with 5-aza as 
(5-aza) 
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position relative to the tumor) and tumoral tissue, to guarantee more reliable results. 
Adjacent tissue is largely used as a control. However, it is still under debate if it should 
be treated as “normal” tissue, due specially to these theories: 1) tumor cell 
contamination – cells extending beyond the invasive tumor margin; 2) tumor 
microenvironment – suggest that normal tissue environment is modified for signals that 
either could promote or suppress tumor development; 3) field cancerization – suggests 
that adjacent tissue is “in an intermediate state between normal and tumor”. 96 Until a 
final confirmation of the reliability of these samples, the following results have clearly 
some limitations. 
 
MGP mRNA expression is higher in tumor tissue  
Comparing the mRNA expression of MGP in matched normal tissue (NT) and 
tumoral tissue (TT) it was possible to determine that MGP expression is increased by 
1.13 (±0.09) times in tumoral tissue (Figure 24). This result is in agreement with 
previous studies that showed a higher expression (20-fold) in metastatic cancer 
(compared to normal epithelium)
68,88
 as well as a correlation between higher MGP 
expression and poor prognosis.
68
 Although an increase of 1.13-fold could appear not so 
expressive, comparing with the 20-fold that occur in metastatic tissue, it is important to 
refer that metastatic tumors are an evolution of primary tumors, with poor prognosis, so 
it can be expected a smaller increase in tumoral tissue.  
 
The absence of fresh samples and results in TCGA database it was not possible 
to try clarify a correlation between mRNA levels and protein levels, however, previous 
Figure 24 | MGP expression is higher in tumoral tissue than in normal tissue (BRCA samples).  A) Comparison 
between MGP expression in NT and TT, per patient – each row represents a patient (n=112) – show a statistical 
different expression of MGP. Results were obtained by two-way ANOVA with p-value < 0.0001 (****). B) MGP is 
increased 1.13 (±0.09) times in TT. 
A B 
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studies did not find a correlation between an increase of mRNA and protein 
expression.
68,87,88
  
 
Methylation pattern and mir155 expression are correlated with MGP 
expression 
Once the implication of mRNA levels as prognosis factor were not demonstrate 
at a protein level, in our lab, Tiago et al postulated the involvement of a post 
transcriptional regulatory mechanism, and it was showed that MGP (protein) is 
significantly repressed by miR-155 in BC cell lines, and in parallel it exists a 
stimulation of cell proliferation and cell invasiveness. 
98
 mi-RNAs are a subclass of 
small noncoding RNA with approximately 22 nucleotides with a tremendous role in 
gene regulation by targeting mRNA for cleavage or translational repression; after 
binding to the target mRNA (by complementary matching bases) miRNA will prevent 
translation or promote mRNA degradation.
98,99
 Mattiske et al had already validated 147 
targets of miRNA-155 with several roles in apoptosis, differentiation, angiogenesis, 
proliferation, and epithelial–mesenchymal transition.100 Epigenetic (e.g. methylation) 
also play an important role in gene expression, so to assess this hypothesis it was 
performed a methylation evaluation in the gene as well as in mir155. 
 
MGP in tumoral tissue is hypomethylated in comparison with matched normal 
tissue 
Using TCGA database in Cancer Genomic Brower, methylation data was 
downloaded and was performed an analyze in matched samples to verify the presence of 
specific methylation in tumor vs normal tissue. For MGP gene there are four probes 
available along the gene (Figure 25): 
CpG1 – cg13302154 CpG2 – cg22221831 CpG3 – cg00431549 CpG4 – cg5360958 
 
Figure 25 | Localization of methylation probes in MGP gene. ATG is the first codon.  
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Figure 26 | Comparison of the methylation status, in four probes localizated in MGP gene, in matched NT and TT 
samples. CpG1, CpG2 and CpG3 are statistically more methylated in normal samples, occuring na hypomethylation on 
tumoral tissue.  
We observed that from the four probes, only one site (CpG4) did not shown 
statistical different methylation status in the matched samples (p(v)=0.0822). The 
remaining probes suggest an hypomethylation in tumoral tissue vs normal tissue. CpG2 
and CpG3 have the most significant difference with p(v)=0.0004 and p(v)=0.0003, 
respectively, and CpG1 with p(v)=0.014 (Figure 26). 
An hypomethylation in cancer is not a novelty, in fact, was the first epigenetic 
abnormality recognized in human tumors.
18
 The hypomethylation in MGP gene suggest 
that some regulatory factors are silenced in the absence of tumors. 
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If we go further, and compare MGP expression and methylation status (Figure 
27) we can observe that it exists in some CpGs a negative correlation between them, 
meaning that a hypomethylation lead to more expression of MGP. Finding the 
regulatory factors that bind in the sequence that corresponds to these CpGs, would be 
very important. It is important to refer that only CpG4 (the one that showed no 
statistical difference in methylation status between NT and TT) have consistent negative 
correlation in normal and tumoral tissue, so next steps should be cautious.  
Figure 27 | Correlation between MGP expression and methylation in normal and tumoral tissue. 
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mir155 is downregulated in tumoral tissue, comparing to matched normal tissue 
Comparing the mir155 expression in matched normal and tumoral tissue it was 
possible to determine that it is more expressed in normal tissue (p(v)<0.0001). In fact 
the expression of mir155 in TT is 0.85 (±0.099s.d) folds the expression in NT (Figure 
28). 
Mattiske (2012) in the first review of the role of mir155 in BC progression 
revealed that high levels of mir155 are associated with “clinicopathologic markers, 
tumor subtype, and poor survival rates”, with all previous work showing a higher 
expression of mir155 in TT rather NT.
100
  
Tiago et al found that an overexpression of mir155 leads to a decrease around 
30% of MGP protein expression (in a breast cell line (MCF7)).
98
 Despite variations in 
mRNA expression did not have always proved to lead to a respective variation in 
protein expression, if we assume that mir155 is decreasing MGP protein by reducing the 
quantity of functional MGP mRNA, our results appear to be consistent with the mir155 
inhibitor role. 
One of the Hallmarks of Cancer is the ability of cancer cells to induce 
angiogenesis. Blood is where oxygen and nutrients needed to feed cells are; vessel 
formation occurs during organogenesis and then is carefully regulated, this way a 
growing cancer is further from the feeding source; inducing angiogenesis is the best 
hypothesis for tumor survival.
13
 MGP was already related with angiogenesis.
101,102
 In 
Kuzontkoski (2010) work of xenografts in immunosuppressed mice, better 
vascularization  was found in MGP rich xenografts, in comparison to control tumors; 
MGP inhibition resulted in smaller and less vascularized xenografts.
101
 This information 
reveals a huge role of MGP in angiogenesis, and therefore on tumor progression. 
Regarding mir155 role in breast cancer, it appears to have a protective effect. 
 The contradictory information of this findings open space to more discuss and 
research.  
Figure 28 | mir155 expression in NT vs TT. mir155 is more expressed in normal tissue (p(v)<0.0001). 
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Final Remarks and Future Perspectives  
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Final Remarks and Future Perspectives  
MGP expression seems to be different according to the type of tumor, but in 
several cases is overexpressed in tumoral tissue (as seen in ovarian cancer, renal cell 
carcinoma and astrocytic gliomas); two independent works in our lab show a higher 
expression of MGP in tumoral tissue in breast cancer as well as in colorectal cancer 
(although in this case a previous report from other group showed a downregulation).  
According to our data the expression of MGP in tumoral and normal tissue is 
associated with epigenetic regulation and posttranscriptional regulation. Appearing to 
exist a negative correlation between: 
 Hypermethylation (of four CpGs islands in MGP gene) and MGP 
expression. Occurs an hypomethylation in cancer tissue. 
 mir155 expression and MGP expression – suggesting that mir155 inhibits 
the expression of MGP; mir155 is higher expressed in normal tissue. 
Adding to this results the fact that MGP inhibits calcification, and that is 
involved in angiogenesis, an hallmark of cancer, it is a good starting point to new 
research, in a way to develop new treatments or tools to make MGP an easy biomarker.  
Our work present new and exciting insights into the expression of MGP variants, 
especially because there is almost none information about it in the literature. Till now, 
results presented as MGP are, presumably, the result of total MGP (both isoforms). Data 
obtained could be the starting line to evaluate MGP isoforms in breast cancer 
progression and to assess the feasibility of using MGP as a prognostic factor or a 
biomarker.  
We confirmed that some cell lines express both variants simultaneous as well 
that the expression of E4 isoform occurred in all samples, but E5 expression was more 
discreet. An overexpression of each variant in CFI-TERT cell line revealed a lower 
migration ratio, comparing to WT cells. Although cell lines are a good research model, 
new studies in fresh samples and/or 3D cultures could give a better insight of the real 
variation of expression of both isoforms as well as the effect of an overexpression of 
each. Invasiveness should also be tested. Knowing that: 
 MGP is overexpressed in tumoral tissue and assuming that the main 
reason is for facilitate angiogenesis, by inhibiting vessels calcification 
and that; 
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 E5 variant have three putative additional sites of gamma carboxylation, 
and that this feature could increase MGP binding capacity, resulting in a 
more powerful inhibition of calcification; 
We could expect that tumoral tissue present more expression of E5 variant than 
normal tissue. Notwithstanding, this theory could not be tested due to a lack of fresh 
samples and databases didn’t distinguish E4 and E5 expression in MGP.  
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Annexes 
Appendix table 1 | TMN stage grouping for breast cancer, as in the 6thEdition of AJCC Cancer Staging 
Manual (2002)28,41 
Stage  TNM  
Stage 0 Tis NO MO Cancer cells are confined in ducts and 
lobules. 
Not spread to surrounding tissue. 
Noninvasive cancer (Tis, NO, MO) 
Stage I T1 NO MO (including 
T1mic)  
 
Stage II A T0 N1 MO 
T1 N1 MO (including T1mic) 
T2 NO MO 
 
Stage II B T2 N1 MO 
T3 NO MO  
 
Stage III A  TO N2 MO 
T1 N2 MO (including T1mic) 
T2 N2 MO  
T3 N1 MO  
T3 N2 MO  
 
Stage III B T4 Any N MO  
Stage III C Any T N3 MO  
Stage IV Any T Any N M1  
  
Appendix table 2 | | Histopathologic classification of Breast Cancers - as in the 6thEdition of AJCC Cancer 
Staging Manual (2002) 41 
In situ Carcinomas Invasive Carcinomas 
NOS NOS 
Intraductal Ductal 
Paget’s disease and 
intraductal 
Inflammatory 
Medullary, NOS  
Medullary with lymphoid stroma 
Mucinous 
b 
 
Papillary (predominantly micropapillary 
pattern) 
Tubular 
Lobular 
Paget’s disease and infiltrating 
Undifferentiated 
Squamous cell 
Adenoid cystic 
Secretory  
cribriform 
 
 
Appendix table 3 | Regional lymph nodes anatomy 
 
  
1. Axillary (ipsilateral): interpectoral (Rotter’s) nodes and lymph nodes along 
axillary vein and its tributaries that may (but not required) divided into: 
a. Level I (low axilla) – LN lateral to the lateral border or pectoralis minor 
muscle. 
b. Level II (mid-axilla) – LN between the medial and lateral borders of the 
pectoralis minor muscle and the interpectoral (Rotter’s) lymph nodes.  
c. Level III (apical axilla) –  LN medial to the medial margin of the pectoralis 
minor muscle, including those designated as apical. 
2. Internal mammary (ipsilateral): LN in the intercostal spaces along the edge of 
the sternum in the endothoracic fascia.  
3. Supraclavicular: LN in the supraclavicular fossa, a triangle defined by the 
omohyod muscle and tendon, the internal jugular vein, and the clavicle and 
subclavicle vein. Adjacent LN outside of this triangle are considered to be lower 
cercical nodes (M!) 
c 
 
Appendix table 4 | Primers used in qRT-PCR. 
Primer Sequence 
hGADPH Forward  5’-TCAACGGATTTGGTCGTATTGGGCG-3’  
hGADPH Reverse 5’-CTCGCTCCTGGAAGATGGTGATGGG-3’  
hMGP Forward 1 (MGP F1) 5’- TGCTGCTACACAAGACCCTGAGACTGA-3’  
hMGP Reverse 4 (MGP Rev4) 5’- CCGAAGTTTTCTTCTTTCTGCCACTCTCC-3’  
hMGP Reverse 5 (MGP Rev5) 5’-GTAGCGTTCGCAAAGTCTGTAGTCATCAC-
3’  
  
Set used in MGP: 
E4 variant – F1 and Rev5 
E5 variant – F1 and Rev4 
 
  
d 
 
Appendix table 5 | Legend of characteristics analyzed in the study population 
Legend of the characteristics analyzed in the study population 
Population: 136 patients with paired samples of tumoral tissue and adjacent tissue, all patients 
are female.  
 
(A) 1 Column: Tumoral type – histology  
1 – Breast Invasive ductal carcinoma (DC) 
2 – Breast invasive lobular carcinoma (LC) 
3 – Others (Mixed [LD+LC], Metaplastic cancer and Paget´s disease of the 
nipple) 
 
(B) 2 Column: Race 
 1 – White 
 2 – Black or African American 
 
(C) 3 Column: Age at diagnosis  
 
(D) 4 Column:  Tumor Stage 
1 – T1 
2 – T2 
3 – T3 
 
(E) 5 Column: Lymph nodes stage 
0 – N0 
1 – N1 
2 – N2 
3 – N3  
 
(F) 6 Column: ER (Estrogen Receptor) status 
 1 – Positive 
 2 – Negative 
 
(G) 7 Column: PR (Progesterone Receptor) status 
1 – Positive 
2 – Negative 
 
(H) 8 Column: HER  status 
1 – Positive 
2 – Negative 
 
(I) 9 Column: AJCC staging 
e 
 
1 – Stage I, IA, IB 
2 – Stage II, IIA, IIB 
3 – Stage III, IIIA IIB, IIIC 
4 – Stage IV  
 
(J) 10 Column: PAM 50 staging in adjacent tissue 
1 – Normal  
2 – Luminal A 
3 – Luminal B 
4 – Basal-Like 
5 – Her+ 
(K) 11 Column: PAM 50 staging in tumoral tissue 
1 – Normal  
2 – Luminal A 
3 – Luminal B 
4 – Basal-Like 
5 – Her+ 
 
(L) 12 Column: Undergo radiation therapy: 
 1 – Positive 
 2 – Negative  
 
(M) 13 Column: Menopause status 
 1 – Peri (6-12 months since last menstrual period (LMP)) 
 2 – Pre (<6 months since LMP and no prior bilateral ovariectomy and not on 
estrogen replacement) 
3 – Post (prior bilateral ovariectomy OR >12 months since LMP with no prior 
hysterectomy) 
 
(N) 14 Column: Anatomic subdivision of breast neoplasia  
 1 – Right breast 
 2 – Left breast  
 
(O) 15 Column: Neoadjuvant history 
 1 – Yes 
 2 – No  
 
(P) 16 Column: Post operative rx and tx 
1 – Yes 
2 – No 
 
f 
 
(Q) 17 Column: Overall Survival in months  
 
(R) 18 Column: MGP expression in adjacent tumor tissue 
 
(S) 19 Column: MGP expression in tumoral tissue 
 
(T) 20 Column: Mir155 expression in adjacent tumor tissue 
 
(U) 21 Column: Mir155 expression in tumoral tissue 
 
Methylation of cg in MGP  
(V) 22 Column: Methylation of cg cg05360958 adjacent tumor tissue 
 
(W)23 Column: Methylation of cg cg05360958 
 
(X) 24 Column: Methylation of cg00431549 adjacent tumor tissue 
 
(Y) 25 Column: Methylation of cg00431549 in tumoral tissue 
 
(Z) 26 Column: Methylation of cg22221831 adjacent tumor tissue 
 
(AA) 27 Column: Methylation of cg22221831 in tumoral tissue 
 
(AB) 28 Column: Methylation of cg13302154 adjacent tumor tissue 
 
(AC) 29 Column: Methylation of cg13302154 in tumoral tissue 
 
